FDA delays meeting discussing COVID-19 vaccine for children under 5

The U.S. Food and Drug Administration announced Friday that it has delayed the public meeting that would have discussed the use of a COVID-19 vaccine in children under the age of 5 years old.

>> Read more trending news

The FDA said the delay is to allow them to review more data, The Associated Press reported.

They had been scheduled to meet on Tuesday, WABC reported.

Pfizer announced Friday that it will be extending its rolling submission to the FDA to amend the emergency use authorization of its COVID-19 vaccine to be used on children from 6 months to 4 years old.

There is a trial going on that is gathering data.

The FDA will then be able to review the data collected for a two- and three-dose regimen and use the information to evaluate and then debate the treatment’s use.

The trial, according to Pfizer, started with 4,500 children between the ages of 6 months and 12 years old in four countries including the U.S.

More children have been enrolled.

The study is looking at the “safety, tolerability, and immunogenicity” of the two-dose treatment spaced 21 days apart in various age groups and varied dosages depending on age, Pfizer said.

The meeting will be delayed until at least April, CNBC reported.

The Centers for Disease Control and Prevention had told state and local health officials that they could receive shipments of a vaccine designed for young children before the end of the month, CNBC reported.